Chemeq's loan terms changed to include revenues, assets
03 November, 2005 by Ruth BeranPerth-based antimicrobial specialist Chemeq (ASX:CMQ) has agreed to vary the terms of the AUD$60 million convertible bonds issued to the company earlier this year, requiring the company to make revenues of at least $4 million in 2005-06 and to have liquid assets of $24 million or more.
Adipogen raises $2.25m for obesity drug, CEO
02 November, 2005 by Helen SchullerUnlisted Brisbane-based company Adipogen has raised a further AUD$2.25 million to support the development of a novel treatment for obesity.
German biotech firm Jerini's shares fall on IPO debut
02 November, 2005 by Staff WritersShares in German biotech firm Jerini fell as much as 6 per cent in their debut on Tuesday amid what traders said was a worsening climate for new listings in Frankfurt and scepticism about biotech offers.
Qld team develops burns therapy device
01 November, 2005 by Helen SchullerA team of Queensland researchers has developed a technology that reduces anxiety and distress during the treatment of burns and may act as a supplement for the use of sedatives for young children.
Cloning rescues rare cattle breed
01 November, 2005 by Graeme O'NeillJust over seven years ago, in August 1998, Dr David Wells of the Ruakua Research Centre in Hamilton announced the successful cloning of the last Enderby Island Cow, the last survivor of a the world's rarest cattle breed.
Thoroughbred specialist to raise up to $4.25 million in backdoor listing
01 November, 2005 by Helen SchullerSouth Australian-based Vet Biotechnology (NSX:VBL) is aiming to raise up to AUD$4.25 million in capital to fund development of a vaccine against 'rattles' disease in racehorses by a backdoor listing on the ASX in late November through Plantcorp.
pSivida commences phase IIb clinical trials
31 October, 2005 by Helen SchullerPerth-based bio-nanotech company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has commenced its phase IIb clinical trials with its BrachySil technology as a potential treatment for inoperable primary liver cancer.
PharmAust names new managing director
31 October, 2005 by Ruth BeranPharmAust (ASX:PAA) has appointed Dr Paul D'Sylva as managing director, also making him responsible for the company's wholly owned subsidiary companies Epichem, Mimotopes and PharmAust Manufacturing.
Opal Therapeutics raises $6m in series A funding
31 October, 2005 by Ruth BeranPrivately-held immunotherapy developer Opal Therapeutics has raised US$6 million in series A financing to develop therapeutic vaccines for HIV and hepatitis C (HCV).
Fonterra to open $15m Melbourne R&D centre
31 October, 2005 by Graeme O'NeillGiant New Zealand-based global dairy company Fonterra has revealed plans to establish a new AUD$15 million global consumer foods R&D centre in Melbourne's eastern suburbs.
No Relenza giveaway without our approval: Biota CEO
28 October, 2005 by Ruth BeranGlaxoSmithKline (GSK) would have to seek approval from Melbourne-based Biota Holdings (ASX:BTA) before the multinational pharmaceutical company could give away any licensing rights to the anti-flu drug Relenza, Biota's CEO Peter Molloy said today.
pSivida signs licensing deal in China
28 October, 2005 by Helen SchullerPerth-based bio-nanotech company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has signed a licence deal worth more than AUD$2.64 million with a US-based firm.
C3 treats first European patient with CellSpray
28 October, 2005 by Helen SchullerTissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.
BRC earns US marketing approval
28 October, 2005 by Helen SchullerThe Brain Resource Company (ASX:BRC) has been granted approval from the US FDA to market its methodology and standardised international human brain database.
Cracks appearing in GM moratoria
28 October, 2005 by Graeme O'NeillThe first cracks have appeared in the Australia-wide moratoria on genetically modified crops, with the decision of the Primary Industries Ministerial Council (PIMC) to adopt a threshold level of 0.9 per cent for adventitious presence of GM grain in conventional canola.
